ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Osilodrostat

Also written as “LCI699” and “osilodrostat”.

Its studies are mostly in Hypertension · Cushing Syndrome · Adrenocortical Hyperfunction · Pituitary ACTH Hypersecretion · Essential Hypertension, led by 2 companies.

Drug pageOsilodrostat: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 17, 201413 company-led studies, 2 open or runningNext primary completion: Jul 21, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only100 open or runningphase 3since Jun 17, 2014Aug 5, 2008none ahead
RECORDATI GROUP32 open or runningphase 4since Nov 19, 2025Jul 20, 2018Jul 21, 2027phase 2 · NCT03708900

Also a collaborator on its studies: Great Lakes Drug Development and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of RECORDATI GROUP only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2018First study: phase 2 study in Cushing SyndromeFirst studyNCT03606408 · 127 enrolled · United States, Argentina, Austria and more
  2. Oct 8, 2018Phase 2 study in Cushing SyndromeNCT03708900 · 12 planned · United States, Belgium, Bulgaria and more
  3. Nov 19, 2025Phase 4 study in HypertensionNCT07247162 · 63 planned · United States

Ahead

  1. Jul 21, 2027Primary completion: phase 2 study in Cushing SyndromeNCT03708900
  2. May 2028Primary completion: phase 4 study in HypertensionNCT07247162

TargetBeta

“An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), ”NCIt, by rule
“Cytochrome P450 11B1 inhibitor”ChEMBL 37, by rule

Studies

All 3 RECORDATI GROUP leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07247162Hypertension · United States4RecruitingMay 202863
NCT03708900Cushing Syndrome · United States, Belgium, Bulgaria and more2RecruitingJul 21, 202712
NCT03606408Cushing Syndrome · United States, Argentina, Austria and more2CompletedNov 16, 2023127

How it is read

Names in the registry

  • “LCI699”, 6 entries
  • “osilodrostat”, 5 entries
  • “Osilodrostat”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.